Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.

Tao RH, Maruyama IN.

J Cell Sci. 2008 Oct 1;121(Pt 19):3207-17. doi: 10.1242/jcs.033399. Epub 2008 Sep 9.

2.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Roskoski R Jr.

Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. Review.

PMID:
15158434
3.

Epidermal growth factor receptor (EGFR) signaling in cancer.

Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.

Gene. 2006 Jan 17;366(1):2-16. Epub 2005 Dec 27. Review.

PMID:
16377102
4.

Active and inactive conformations of the epidermal growth factor receptor.

Ferguson KM.

Biochem Soc Trans. 2004 Nov;32(Pt 5):742-5. Review.

PMID:
15494003
5.

Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.

Sanderson MP, Dempsey PJ, Dunbar AJ.

Growth Factors. 2006 Jun;24(2):121-36. Review.

PMID:
16801132
6.

Trafficking of the ErbB receptors and its influence on signaling.

Wiley HS.

Exp Cell Res. 2003 Mar 10;284(1):78-88. Review.

PMID:
12648467
7.

Role of HER receptors family in development and differentiation.

Casalini P, Iorio MV, Galmozzi E, Ménard S.

J Cell Physiol. 2004 Sep;200(3):343-50. Review.

PMID:
15254961
8.

ErbB and HB-EGF signaling in heart development and function.

Iwamoto R, Mekada E.

Cell Struct Funct. 2006;31(1):1-14. Review.

9.

EGFR family: structure physiology signalling and therapeutic targets.

Burgess AW.

Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Review.

PMID:
18800267
10.

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.

Fuller SJ, Sivarajah K, Sugden PH.

J Mol Cell Cardiol. 2008 May;44(5):831-54. doi: 10.1016/j.yjmcc.2008.02.278. Epub 2008 Mar 4. Review.

PMID:
18430438
11.

Type I growth factor receptors: current status and future work.

Gullick WJ.

Biochem Soc Symp. 1998;63:193-8. Review.

PMID:
9513723
12.

The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.

Ward CW, Lawrence MC, Streltsov VA, Adams TE, McKern NM.

Trends Biochem Sci. 2007 Mar;32(3):129-37. Epub 2007 Feb 5. Review.

PMID:
17280834
13.

Role of heregulin in human cancer.

Breuleux M.

Cell Mol Life Sci. 2007 Sep;64(18):2358-77. Review.

PMID:
17530167
14.

Targeting ligand cleavage to inhibit the ErbB pathway in cancer.

Zhou BB.

Ann N Y Acad Sci. 2005 Nov;1059:56-60. Review.

PMID:
16382043
15.

Structural relationships between the insulin receptor and epidermal growth factor receptor families and other proteins.

Ward CW, Garrett TP.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):630-8. Review.

PMID:
15503865
16.

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.

Schlessinger J.

Cell. 2002 Sep 20;110(6):669-72. Review.

17.

Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers.

O'Rourke DM, Zhang X, Greene MI.

Proc Assoc Am Physicians. 1997 May;109(3):209-19. Review.

PMID:
9154637
18.

Targeting ErbB receptor signaling: a pan-ErbB approach to cancer.

Britten CD.

Mol Cancer Ther. 2004 Oct;3(10):1335-42. Review.

19.

ErbB receptors and their ligands in the breast.

Zahnow CA.

Expert Rev Mol Med. 2006 Sep 20;8(23):1-21. Review.

PMID:
16984691
20.

The EGF receptor family: spearheading a merger of signaling and therapeutics.

Bublil EM, Yarden Y.

Curr Opin Cell Biol. 2007 Apr;19(2):124-34. Epub 2007 Feb 20. Review.

PMID:
17314037

Supplemental Content

Support Center